priva-atorvastatin comprimé
pharmapar inc - atorvastatine (atorvastatine calcique) - comprimé - 40mg - atorvastatine (atorvastatine calcique) 40mg - hmg-coa reductase inhibitors
priva-atorvastatin comprimé
pharmapar inc - atorvastatine (atorvastatine calcique) - comprimé - 80mg - atorvastatine (atorvastatine calcique) 80mg - hmg-coa reductase inhibitors
atorvastatin comprimé
nora pharma inc - atorvastatine (atorvastatine calcique) - comprimé - 10mg - atorvastatine (atorvastatine calcique) 10mg - hmg-coa reductase inhibitors
atorvastatin comprimé
nora pharma inc - atorvastatine (atorvastatine calcique) - comprimé - 20mg - atorvastatine (atorvastatine calcique) 20mg - hmg-coa reductase inhibitors
atorvastatin comprimé
nora pharma inc - atorvastatine (atorvastatine calcique) - comprimé - 40mg - atorvastatine (atorvastatine calcique) 40mg - hmg-coa reductase inhibitors
atorvastatin comprimé
nora pharma inc - atorvastatine (atorvastatine calcique) - comprimé - 80mg - atorvastatine (atorvastatine calcique) 80mg - hmg-coa reductase inhibitors
kisplyx 4 mg capsules
eisai pharma ag - lenvatinibum - capsules - lenvatinibum 4 mg ut lenvatinibi mesilas, calcii carbonas, mannitolum, cellulosum microcristallinum, hydroxypropylcellulosum, hydroxypropylcellulosum substitutum humile, talcum, kapselhülle: hypromellosum, e 171, e 172 (flavum), e 172 (rubrum), drucktinte: lacca, e 172 (nigrum), kalii hydroxidum, propylenglycolum, pro capsula. - behandlung von fortgeschrittenem nierenzellkarzinom (rcc) - synthetika
kisplyx 10 mg capsules
eisai pharma ag - lenvatinibum - capsules - lenvatinibum 10 mg ut lenvatinibi mesilas, calcii carbonas, mannitolum, cellulosum microcristallinum, hydroxypropylcellulosum, hydroxypropylcellulosum substitutum humile, talcum, kapselhülle: hypromellosum, e 171, e 172 (flavum), e 172 (rubrum), drucktinte: lacca, e 172 (nigrum), kalii hydroxidum, propylenglycolum, pro capsula. - behandlung von fortgeschrittenem nierenzellkarzinom (rcc) - synthetika
kisplyx
eisai gmbh - mésilate de lenvatinib - carcinome, cellule rénale - agents antinéoplasiques - kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (rcc):in combination with pembrolizumab, as first-line treatment (see section 5. in combination with everolimus, following one prior vascular endothelial growth factor (vegf)-targeted therapy.
keytruda poudre pour solution
merck canada inc - pembrolizumab - poudre pour solution - 50mg - pembrolizumab 50mg - antineoplastic agents